Karyopharm EVP reports PSU vesting and small tax sale

Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported two transactions in common stock.

Rhea-AI Filing Summary

Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported two transactions in common stock. On May 13, 2026, she acquired 947 shares at no cost from performance-based restricted stock units earned after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified. On May 14, 2026, she sold 324 shares at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan to cover withholding tax from the PSU vesting, described as non-discretionary. Following these transactions, she directly owns 107,940 shares of Karyopharm common stock.

Insider Trade Summary

Net Seller: 324 shares

Net Sell 2 txns

Insider Cheng Sohanya Roshan

Role EVP & Chief Commercial Officer

Sold 324 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	324	$9.50	$3K
Grant/Award	Common Stock	947	$0.00	$0.00

Holdings After Transaction: Common Stock — 107,940 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026.
2. F2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 324 shares Sale price: $9.50 per share Shares acquired from PSUs: 947 shares +2 more

5 metrics

Shares sold 324 shares Open-market sale on May 14, 2026 at $9.50 per share

Sale price $9.50 per share Broker-assisted sale of 324 shares on May 14, 2026

Shares acquired from PSUs 947 shares PSU award earned and granted on May 13, 2026

Post-transaction holdings 107,940 shares Direct ownership after May 14, 2026 sale

Net shares sold 324 shares Net buy/sell shares reported for this Form 4

Key Terms

performance-based restricted stock units, durable automatic sale instruction plan, withholding tax liability, Phase 3 XPORT-EC-042 trial

4 terms

performance-based restricted stock units financial

"Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022"

withholding tax liability financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs"

Phase 3 XPORT-EC-042 trial technical

"based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial"

FAQ

What insider transactions did Karyopharm (KPTI) EVP Sohanya Roshan Cheng report?

She reported two transactions: an acquisition of 947 shares of Karyopharm common stock from vested performance-based RSUs on May 13, 2026, and a sale of 324 shares at $9.50 per share on May 14, 2026.

Why did Karyopharm (KPTI) executive Sohanya Roshan Cheng sell 324 shares?

The 324-share sale at $9.50 per share was executed by a broker under a durable automatic sale instruction plan to satisfy withholding tax liability from PSU vesting, and the filing states it did not represent a discretionary trade by her.

How many Karyopharm (KPTI) shares does EVP Sohanya Roshan Cheng own after the Form 4 transactions?

After the reported Form 4 transactions, EVP & Chief Commercial Officer Sohanya Roshan Cheng directly owns 107,940 shares of Karyopharm Therapeutics common stock, according to the totals listed following the May 14, 2026 sale transaction.

What triggered the PSU vesting for Karyopharm (KPTI) executive Sohanya Roshan Cheng?

The performance-based RSUs vested after achievement of a clinical milestone for complete enrollment in Karyopharm’s Phase 3 XPORT-EC-042 trial, which the company’s Compensation Committee certified on May 13, 2026, leading to the 947-share award.

Were the Karyopharm (KPTI) insider sales by Sohanya Roshan Cheng part of a trading plan?

Yes. The filing explains the 324-share sale was completed under a durable automatic sale instruction plan adopted on June 7, 2022, specifically to cover tax withholding from PSU vesting, and is described as non-discretionary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheng Sohanya Roshan

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		A		947(1)	A	$0.0	108,264	D
Common Stock	05/14/2026		S(2)		324	D	$9.5	107,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026.

2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)